| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 3,042 | 3,812 | 3,410 | 3,137 | 3,312 | 3,581 | 3,699 | 3,717 | 3,510 | 3,584 | 4,102 | 3,887 | 3,536 | 4,016 | 4,081 | 3,985 | 4,366 | 3,973 | 4,365 | 4,307 | 4,395 | 4,342 | 5,026 | 5,241 | 4,645 | 5,536 | 5,547 | 5,534 | 5,288 | 5,421 | 5,882 | 5,845 | 5,801 | 6,406 | 6,766 | 6,690 | 6,332 | 6,785 | 7,152 | 7,183 |
| Expenses | 2,585 | 2,784 | 2,669 | 2,688 | 3,138 | 3,039 | 3,070 | 2,970 | 3,076 | 2,879 | 3,278 | 3,095 | 3,219 | 3,213 | 3,310 | 3,300 | 3,443 | 3,084 | 3,486 | 3,613 | 3,743 | 3,297 | 3,862 | 3,938 | 3,810 | 4,283 | 4,294 | 4,248 | 4,568 | 4,232 | 4,526 | 4,403 | 4,748 | 4,835 | 4,944 | 5,051 | 4,847 | 4,978 | 5,165 | 5,084 |
| EBITDA | 457 | 1,028 | 741 | 450 | 174 | 543 | 629 | 748 | 434 | 705 | 824 | 792 | 317 | 803 | 771 | 685 | 923 | 889 | 879 | 694 | 652 | 1,045 | 1,164 | 1,303 | 835 | 1,253 | 1,253 | 1,286 | 720 | 1,190 | 1,356 | 1,442 | 1,053 | 1,571 | 1,821 | 1,639 | 1,484 | 1,807 | 1,986 | 2,099 |
| Operating Profit % | 13 % | 26 % | 21 % | 12 % | 4 % | 15 % | 16 % | 17 % | 12 % | 16 % | 18 % | 19 % | 8 % | 16 % | 16 % | 16 % | 19 % | 21 % | 18 % | 15 % | 13 % | 23 % | 22 % | 24 % | 17 % | 22 % | 22 % | 22 % | 13 % | 20 % | 21 % | 23 % | 16 % | 23 % | 25 % | 22 % | 20 % | 25 % | 26 % | 27 % |
| Depreciation | 136 | 149 | 158 | 177 | 270 | 204 | 229 | 258 | 632 | 213 | 302 | 522 | 285 | 241 | 282 | 293 | 510 | 268 | 283 | 278 | 346 | 269 | 265 | 248 | 285 | 261 | 253 | 248 | 290 | 254 | 299 | 272 | 346 | 239 | 290 | 233 | 288 | 247 | 272 | 280 |
| Interest | 43 | 64 | 64 | 31 | 48 | 32 | 35 | 59 | 33 | 28 | 42 | 9 | 35 | 35 | 44 | 44 | 45 | 52 | 46 | 46 | 53 | 46 | 39 | 48 | 28 | 30 | 38 | 21 | 18 | 18 | 26 | 32 | 34 | 16 | 26 | 30 | 18 | 18 | 15 | 15 |
| Profit Before Tax | 390 | 892 | 595 | 322 | -82 | 401 | 444 | 514 | -137 | 557 | 574 | 340 | 199 | 620 | 509 | 449 | 501 | 663 | 681 | 506 | 328 | 799 | 926 | 1,022 | 544 | 996 | 996 | 1,054 | 448 | 975 | 1,100 | 1,218 | 745 | 1,375 | 1,594 | 1,474 | 1,259 | 1,611 | 1,789 | 1,916 |
| Tax | 106 | 242 | 43 | 54 | 5 | 57 | 74 | 129 | -74 | 132 | 139 | -63 | 46 | 175 | 142 | 127 | 144 | 216 | 207 | 167 | 89 | 233 | 266 | 270 | 132 | 286 | 287 | 297 | 77 | 268 | 303 | 410 | 224 | 377 | 439 | 405 | 327 | 436 | 484 | 342 |
| Net Profit | 284 | 650 | 552 | 269 | -87 | 344 | 370 | 385 | -63 | 425 | 435 | 404 | 153 | 446 | 367 | 322 | 358 | 447 | 475 | 339 | 239 | 566 | 659 | 752 | 412 | 710 | 709 | 757 | 371 | 706 | 797 | 808 | 522 | 998 | 1,155 | 1,068 | 932 | 1,176 | 1,305 | 1,575 |
| EPS in ₹ | 3.24 | 8.09 | 6.76 | 3.24 | -1.16 | 4.22 | 4.41 | 4.66 | -0.77 | 5.08 | 5.25 | 4.98 | 2.22 | 5.60 | 4.68 | 4.12 | 4.56 | 5.93 | 5.85 | 4.35 | 3.05 | 7.17 | 8.25 | 9.28 | 5.13 | 8.86 | 8.82 | 9.03 | 4.49 | 8.51 | 9.78 | 9.92 | 6.51 | 12.34 | 14.01 | 13.08 | 11.63 | 14.58 | 16.13 | 19.45 |
Cipla
1,441.75
-21.00
(-1.44%)
Market Cap
1,16,437.75 Cr
EPS
51.05
PE Ratio
23.67
Dividend Yield
0.89 %
Industry
Healthcare52 Week High
1,702.05
52 Week low
1,317.25
PB Ratio
4.16
Debt to Equity
0.03
Sector
Pharmaceuticals
Live Chart 
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from32 analysts
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
| 1,655.75 | 3,97,269.89 | 32.77 | 49,887.20 | 12.06 | 9,648 | 13.77 | 37.72 | |
| 5,541.25 | 1,47,102.78 | 70.79 | 8,184.00 | 0.89 | 1,600 | 64.53 | 39.06 | |
| 1,441.75 | 1,16,437.75 | 23.67 | 26,520.70 | 14.17 | 4,155 | 47.38 | 53.19 | |
| 3,065.45 | 1,03,748.76 | 55.81 | 10,785.70 | 11.59 | 1,656 | 13.54 | 48.49 | |
| 1,115.90 | 93,111.91 | 17.40 | 28,905.40 | 12.36 | 5,578 | 1.69 | 32.01 | |
| 2,209.05 | 91,138.09 | 45.68 | 10,615.60 | 19.57 | 1,942 | -16.38 | 36.72 | |
| 900.40 | 90,601.31 | 19.82 | 19,831.50 | 13.82 | 3,831 | 29.92 | 43.14 | |
| 1,973.30 | 90,021.47 | 31.98 | 20,141.50 | 19.94 | 1,936 | 38.82 | 48.40 | |
| 30,568.30 | 64,955.50 | 48.79 | 6,097.20 | 10.80 | 1,201 | 16.01 | 59.83 | |
| 1,089.55 | 63,281.24 | 18.00 | 29,559.20 | 17.55 | 3,169 | -10.04 | 42.91 |
Growth Rate
Revenue Growth
14.17 %
Net Income Growth
46.55 %
Cash Flow Change
27.68 %
ROE
29.60 %
ROCE
23.78 %
EBITDA Margin (Avg.)
12.03 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 15,718 | 21,128 | 21,037 | 22,861 | 23,963 | 23,663 | 25,152 | 27,101 | 29,463 | 32,718 |
| Fixed Assets | 6,830 | 9,369 | 9,492 | 9,950 | 9,608 | 9,683 | 9,516 | 9,683 | 9,161 | 9,607 |
| Current Assets | 7,591 | 8,841 | 8,736 | 10,814 | 12,427 | 11,706 | 13,210 | 14,711 | 16,805 | 19,392 |
| Capital Work in Progress | 581 | 2,061 | 1,683 | 981 | 676 | 825 | 969 | 766 | 1,093 | 1,153 |
| Investments | 390 | 758 | 973 | 1,259 | 2,554 | 1,471 | 2,710 | 2,551 | 3,662 | 5,449 |
| Other Assets | 7,917 | 8,940 | 8,889 | 10,670 | 11,125 | 11,684 | 11,957 | 14,101 | 15,547 | 16,509 |
| Total Liabilities | 15,718 | 21,128 | 21,037 | 22,861 | 23,963 | 23,663 | 25,152 | 27,101 | 29,463 | 32,718 |
| Current Liabilities | 3,881 | 7,776 | 3,374 | 3,832 | 3,772 | 4,393 | 4,591 | 4,913 | 5,110 | 5,246 |
| Non Current Liabilities | 854 | 1,486 | 4,682 | 4,447 | 4,848 | 3,212 | 1,975 | 1,071 | 640 | 670 |
| Total Equity | 10,982 | 11,866 | 12,982 | 14,582 | 15,344 | 16,057 | 18,586 | 21,117 | 23,714 | 26,802 |
| Reserve & Surplus | 10,629 | 11,356 | 12,383 | 14,068 | 14,851 | 15,602 | 18,165 | 20,680 | 23,246 | 26,545 |
| Share Capital | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 162 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 389 | 312 | -248 | 243 | -345 | 234 | 141 | -132 | -97 | -49 |
| Investing Activities | -950 | -4,533 | -1,304 | -834 | -1,688 | 114 | -2,374 | -1,858 | -2,376 | -2,983 |
| Operating Activities | 1,173 | 1,741 | 2,382 | 1,463 | 1,691 | 3,068 | 3,755 | 3,326 | 3,238 | 4,134 |
| Financing Activities | 165 | 3,104 | -1,326 | -386 | -349 | -2,949 | -1,240 | -1,600 | -958 | -1,200 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 36.73 % | 36.72 % | 36.12 % | 36.11 % | 33.63 % | 33.61 % | 33.61 % | 33.61 % | 33.55 % | 33.47 % | 33.47 % | 33.47 % | 33.47 % | 30.91 % | 30.92 % | 29.19 % |
| FIIs | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.00 % | 0.00 % | 0.00 % | 25.74 % | 25.73 % | 25.83 % | 27.81 % | 28.80 % | 26.65 % |
| DIIs | 16.79 % | 15.91 % | 17.41 % | 17.61 % | 17.72 % | 17.12 % | 19.71 % | 21.13 % | 22.10 % | 24.34 % | 24.18 % | 24.33 % | 24.42 % | 24.95 % | 24.16 % | 27.71 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 16.24 % | 16.14 % | 16.01 % | 15.97 % | 15.55 % | 15.41 % | 14.83 % | 14.72 % | 14.85 % | 14.66 % | 14.45 % | 14.34 % | 14.20 % | 14.24 % | 14.16 % | 14.29 % |
| Others | 30.23 % | 31.22 % | 30.47 % | 30.30 % | 33.10 % | 33.86 % | 31.84 % | 30.53 % | 29.50 % | 27.53 % | 2.16 % | 2.12 % | 2.08 % | 2.09 % | 1.95 % | 2.15 % |
| No of Share Holders | 3,64,796 | 4,08,401 | 4,10,831 | 4,51,365 | 4,18,584 | 4,18,910 | 3,88,864 | 4,04,182 | 4,75,293 | 4,66,513 | 4,26,861 | 4,25,731 | 4,36,154 | 4,63,569 | 4,70,234 | 5,25,114 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 2 | 3 | 3 | 4 | 5 | 5 | 8.5 | 13 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.37 | 0.57 | 0.71 | 0.49 | 0.49 | 0.56 | 0.57 | 0.89 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
USFDA Inspection At Analytical Testing Facility Of Sitec In Mahape Navi Mumbai India
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Announcement under Regulation 30 (LODR)-Updates on Acquisition
Announcement under Regulation 30 (LODR)-Investor Presentation
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Update On USFDA Inspection At CompanyS Manufacturing Facility In Virgonagar Bengaluru India
Announcement under Regulation 30 (LODR)-Acquisition
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Integrated Filing (Financial)
Announcement under Regulation 30 (LODR)-Change in Management
Board Meeting Outcome for Outcome Of Board Meeting Dated 28Th January 2025
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Investor Presentation
Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months Ended 31St December 2024.
Announcement under Regulation 30 (LODR)-Change in Management
USFDA Inspection At Manufacturing Facility Of Medispray In Kundaim Goa India
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Tuesday 28Th January 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Disclosure Under Regulation 30(5) Of The SEBI (LODR) Regulations, 2015
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
USFDA Inspection At Company''s Manufacturing Facility In Virgonagar, Bengaluru, India
Announcement under Regulation 30 (LODR)-Change in Directorate
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Update On USFDA Inspection At Company''s Manufacturing Facility In Goa, India
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Announcement under Regulation 30 (LODR)-Newspaper Publication
Board Meeting Outcome for Outcome Of Board Meeting Dated 29Th October 2024
Announcement under Regulation 30 (LODR)-Investor Presentation
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended 30Th September 2024
Announcement under Regulation 30 (LODR)-Updates on Acquisition
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations, 2015')
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements), Regulations, 2015 (''Listing Regulations'')
Announcement under Regulation 30 (LODR)-Acquisition
Announcement under Regulation 30 (LODR)-Newspaper Publication
Company Filings to Exchanges
Technical Indicators
RSI(14)
Neutral 53.19
ATR(14)
Less Volatile 32.55
STOCH(9,6)
Neutral 43.59
STOCH RSI(14)
Overbought 84.44
MACD(12,26)
Bullish 0.83
ADX(14)
Weak Trend 12.06
UO(9)
Bearish 52.25
ROC(12)
Downtrend And Accelerating -0.10
WillR(14)
Neutral -34.83
About Cipla
Cipla Ltd is a leading Indian pharmaceutical company that manufactures, develops, and markets a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company operates in two segments: Pharmaceuticals and New ventures. Its product portfolio includes complex generics and drugs in respiratory, anti-retroviral, urology, cardiology, anti-infective, and CNS therapeutic areas. Cipla has a global presence with manufacturing facilities and operations in India and international markets, including the United States, South Africa, and other countries. The company focuses on developing and producing generic and branded generic medicines, as well as expanding into consumer healthcare, biosimilars, and specialty business through its New ventures segment.
Website
Chairperson NameY K Hamied
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
